{"symbol":"REGN","fiscalQuarter":"Q4-2015","reportDate":"2016-02-09","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q4-2015","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Down 6.29%","keyNumbers":[{"metric":"EPS","actual":"$2.83","expected":"N/A","surprise":"+5.01%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our EPS performance this quarter.","Our focus remains on advancing our pipeline."],"summary":"Management expressed satisfaction with the EPS results, indicating a commitment to pipeline development. However, they did not provide specific guidance for future performance."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron Pharmaceuticals reported better-than-expected earnings per share, but the stock fell by 6.29% following the announcement. Investors may have reacted negatively due to the lack of revenue details and guidance. The cautious tone from management suggests a focus on long-term growth rather than immediate financial targets.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q4 2015 earnings: EPS beat by 5.01%. Stock down 6.29%. Full breakdown."}}